Abstract:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and anti-angiogenic drugs have individually demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Recent studies demonstrate that the combination of anti-EGFR and anti-angiogenesis can more significantly enhance clinical benefit, and even can remit EGFR-TKIs resistance in the treatment of advanced NSCLC. According to the different kinds of antiangiogenesis drugs, recent clinical studies mainly include the combination of antivascular endothelial growth factor monoclonal antibody bevacizumab plus EGFR-TKIs and multi-targeted receptor antiangiogenic tyrosine kinase inhibitor plus EGFR-TKIs, and the former results show a more significant improvement in terms of safety and efficacy in the treatment of advanced NSCLC. Therefore, the combination of bevacizumab plus EGFR-TKIs can be used as a new treatment standard in the treatment of some patients with NSCLC.

Key words:Carcinoma, non-small-cell lung,Angiogenesis inhibitors,Epidermal growth factor receptor-tyrosine kinase inhibitors